Disease

Zogby Interactive Survey Finds Concern Over Vaccine Safety Cited As Top Reason

Utica, NY - As the H1N1 swine flu vaccine becomes increasingly available, 46% of adults who are considered by the CDC to be members of high priority groups plan to ignore the CDC's recommendation for vaccination. The Zogby International interactive survey also finds that the top reasons high risk adults plan to skip the vaccine include concern over the safety of the vaccine (38%) and a general sense that they simply do not need the vaccine (32%).    » read more »

NEW YORK & GENEVA -- Pfizer Inc and Drugs for Neglected Diseases initiative (DNDi) have signed an agreement that is designed to facilitate advancements in the battle against human African trypanosomiasis (HAT), visceral leishmaniasis (VL) and Chagas disease, which afflict vulnerable populations in the developing world. Under the agreement, DNDi will have access to the Pfizer library of novel chemical entities, in order to screen it for compounds that have the potential to be developed into new treatments.    » read more »

Washington, DC, Nov 17 -- Congresswoman Maxine Waters (D-CA) introduced H. Res. 910 today, National Memory Screening Day, to promote awareness of Alzheimer’s disease, to support the development of a national health policy on dementia screening and care, and to encourage Americans concerned about memory loss to be screened. The resolution has bipartisan support.

“I am promoting awareness of Alzheimer’s disease because scientific research has demonstrated that early medical treatment would be beneficial to millions of Americans who suffer from Alzheimer’s and early access to counseling and support services is helpful to those who are caregivers,” said Congresswoman Waters. “Awareness and early detection of memory loss therefore are essential.”    » read more »

Bill Will Guarantee Up to Seven Days of Paid Sick Leave for Workers Infected By the H1N1 Virus

November 17, 2009 -- Senator Chris Dodd (D-CT) and Congresswoman Rosa DeLauro (D-CT-3) today will introduce emergency legislation that will guarantee paid sick days for those who are infected by the H1N1 virus. Last week, Dodd chaired, and Congresswoman DeLauro testified at, a hearing of the Health, Education, Labor, and Pensions (HELP) Subcommittee on Children and Families in response to the H1N1 pandemic.    » read more »

November 17, 2009 -- The current pandemic of H1N1 influenza highlights vulnerabilities in the world’s plans for dealing with widespread health emergencies, but also offers opportunities to better prepare for more deadly epidemics that will surely arise in the future, experts said at a recent symposium held in New York City.

The 16 October meeting, sponsored by the Council on Foreign Relations and the journal Science, brought together experts on science, economics, public health and foreign relations to assess the impact of the flu pandemic and future implications.    » read more »

US interim data show lower doses of antigen may suffice to generate a protective immune response against A(H1N1)

Basel, November 17, 2009 - Novartis announced today new interim data from ongoing clinical trials demonstrating that a single 7.5µg dose of the company's influenza A(H1N1) 2009 unadjuvanted vaccine, half of the currently-approved US dose, fulfilled immune response criteria associated with protection in adults and the elderly (>=65 years of age).    » read more »

Last Week Schumer Requested The FTC Step Up Enforcement Actions Against Websites Peddling Fake H1N1 Cures and Prevention Methods

November 16, 2009 -- Today, U.S. Senator Charles E. Schumer announced that the Federal Trade Commission (FTC) is embarking on a major crackdown on companies selling phony H1N1 remedies. As the problem of fake remedies grows worse, and concerns about the H1N1 flu increase, the FTC announced that they would take further enforcement action against ten companies that are peddling fake H1N1 remedies on-line.    » read more »

13 November 2009 -- As of 8 November 2009, worldwide more than 206 countries and overseas territories or communities have reported laboratory confirmed cases of pandemic influenza H1N1 2009, including over 6250 deaths.

As many countries have stopped counting individual cases, particularly of milder illness, the case count is likely to be significantly lower than the actual number of cases that have occurred. WHO is actively monitoring the progress of the pandemic through frequent consultations with the WHO Regional Offices and member states and through monitoring of multiple sources of data.

Situation update:    » read more »

A domain of the NR2B subunit of the NMDA receptor is mapped in exquisite detail

November 13, 2009 --
Cold Spring Harbor, NY -- A team of scientists at Cold Spring Harbor Laboratory (CSHL) reports on Thursday their success in solving the molecular structure of a key portion of a cellular receptor implicated in Alzheimer's, Parkinson's, and other serious illnesses.

Assistant Professor Hiro Furukawa, Ph.D., and colleagues at CSHL, in cooperation with the National Synchrotron Light Source at Brookhaven National Laboratory, obtained crystal structures for one of several "subunits" of the NMDA receptor. This receptor, formally called the N-methyl-D-aspartate receptor, belongs to a family of cellular receptors that mediate excitatory nerve transmission in the brain.    » read more »

Announces Counties Are Conducting Vaccination Clinics As More H1N1 Vaccine Becomes Available

November 13, 2009 -- New York Governor David A. Paterson today announced that county health departments across New York are mobilizing to conduct H1N1 flu vaccination clinics as more vaccine becomes available in the State.

“Due to delays in manufacturing the H1N1 vaccine, our statewide vaccination campaign has not been mobilized as rapidly as we had hoped,” Governor Paterson said. “As we move into the middle of November, more H1N1 vaccine is becoming available, and health care providers are receiving more shipments. Some county health departments have already held vaccination clinics, and others are gearing up to hold them in the next two weeks.”    » read more »

ANNAPOLIS, MD (November 13, 2009) – Maryland Governor Martin O'Malley issued the second in a series of online H1N1 (Swine) Flu web updates on H1N1 (Swine) Flu today, including a status update on the spread of the disease and an update on the seasonal flu and H1N1 vaccines. To date, state officials have ordered 100% of the H1N1 vaccinations available to Maryland distributors, more than 750,000 doses.    » read more »

November 14, 2009 -- AUGUSTA – Two more deaths have been reported linked to H1N1 influenza in Maine, bringing the total to five since August, and a Kennebec County long-term care facility is experiencing an outbreak of H1N1, according to the Maine Center for Disease Control.

A Hancock County resident between the ages of 25 years old and 50 years old and a Kennebec County resident older than 65 years old died last week. Both had H1N1 and both had underlying conditions.    » read more »

Panenza®, non-adjuvanted pandemic vaccine, licensed for use in adults and children 6 months of age and older

Lyon, France – November 16, 2009 - Sanofi Pasteur, the vaccines division of the sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY) announced today that the French drug agency Afssaps (Agence française de sécurité sanitaire des produits de santé) has granted marketing authorization in France for Panenza®, its non-adjuvanted Influenza A(H1N1) 2009 monovalent vaccine, produced at Sanofi Pasteur’s facility in Val de Reuil, France. The vaccine was made available to French health authorities.    » read more »

Swissmedic approval allows Novartis to begin shipments of Celtura to Switzerland, providing supplies of A(H1N1) vaccine immediately

Basel, November 13, 2009 - Novartis announced today that Celtura®, the company's adjuvanted cell culture-based Influenza A(H1N1) 2009 monovalent vaccine, has received approval in Switzerland from Swissmedic, the Swiss Agency for Therapeutic Products.

This is the second marketing approval for the cell-culture based A(H1N1) pandemic vaccine in Europe. Celtura was approved in Germany earlier in November 2009. The company also has submitted a registration for Celtura in Japan, and will seek approval in a number of other countries.    » read more »

11/13/09 -- Washington, DC -- Yesterday, Congressman Tim Bishop (NY-1) and members of the New York Congressional Delegation sent a bipartisan letter to federal, state and city officials expressing outrage over reports that over a dozen Wall Street firms were approved to receive some of the limited H1N1 vaccines available to the public. According to BusinessWeek, these private companies have received as many as 1200 units each in recent weeks as colleges, nursing homes and schools face severe shortages.    » read more »